Lv51
820 积分 2023-12-14 加入
Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial
57分钟前
已完结
Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial
4小时前
已完结
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
1个月前
已完结
Measurable residual disease assessment in multiple myeloma
1个月前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
1个月前
已完结
Derivation of the sledai. A disease activity index for lupus patients
1个月前
已完结
Association of Daratumumab Use With Ocular Events in a Case Series of US Adults
3个月前
已完结
Multiple myeloma
8个月前
已关闭
Multiple myeloma
8个月前
已完结
Tumour lysis syndrome
9个月前
已完结
皖公网安备34019202002308
